Paclitaxel for malignant pleural mesothelioma: A phase II study of the EORTC Lung Cancer Cooperative Group Academic Article uri icon


MeSH Major

  • Antineoplastic Agents, Phytogenic
  • Mesothelioma
  • Paclitaxel
  • Pleural Neoplasms


  • The EORTC Lung Cancer Cooperative Group undertook a phase II study of paclitaxel in 25 chemotherapy-naive patients with malignant pleural mesothelioma. Paclitaxel was given intravenously at a dose of 200 mg m-2 as a 3 h infusion every 3 weeks, after standard premedication with corticosteroids and antihistamines. This regimen was well tolerated, with < 4% of cycles resulting in severe toxicity. No major objective responses were observed and ten patients had stable disease. Median survival time was 39 weeks and the 1 year survival rate was 30%. In conclusion, paclitaxel at the dose and schedule investigated in this trial had no major activity in the treatment of malignant pleural mesothelioma.

publication date

  • January 1996



  • Academic Article



  • eng

PubMed Central ID

  • PMC2074723

Digital Object Identifier (DOI)

  • 10.1038/bjc.1996.465

PubMed ID

  • 8826866

Additional Document Info

start page

  • 961

end page

  • 3


  • 74


  • 6